🧬 Chapter 511 · Hemoglobinopathies

Nelson Textbook of Pediatrics 22nd Edition | Sickle cell disease (HbSS, HbSC, HbSβ-thal) — newborn screening, hydroxyurea, chronic transfusions, TCD stroke prevention, acute chest syndrome, gene therapy (CRISPR, lentiviral). Other hemoglobinopathies: HbC, HbE, HbD, unstable hemoglobins, high/low affinity variants, methemoglobinemia (M hemoglobins, NADH-cytochrome b5 reductase deficiency), HPFH, thalassemia syndromes overview.

🌐 paeds.online — Pakistan's Pediatric Platform

📋 30 Clinical Scenarios — Hemoglobinopathies (Sickle Cell & Others)

📇 High‑Yield Review Cards (Hemoglobinopathies)

🩺 Clinical Recognition: Sickle Cell Disease & Other Hemoglobinopathies

Select a presentation for diagnostic clues and management.

📋 Stepwise Management of Sickle Cell Disease (Nelson Ch 511.1)

🔑 Key Points — Nelson Ch 511
• Newborn screening mandatory in US. HbFS → HbSS, HbSβ⁰-thal, or HbS-HPFH.
• Prophylactic penicillin start by 2-4 months until at least 5 years.
• Hydroxyurea (20-35 mg/kg/day) recommended for all children with HbSS starting at 9 months to reduce pain, ACS, hospitalizations.
• TCD screening ages 2-16 years. Abnormal (>200 cm/sec) → chronic transfusions to reduce stroke risk.
• Fever emergency → empiric IV ceftriaxone, CBC, cultures.
• Gene therapy (Casgevy, Lyfgenia) approved for >12 years with recurrent VOC.

    ⚡ Reflex Prompts — Clinical Decisions in Hemoglobinopathies

    📖 Summary: Hemoglobinopathies — Nelson Ch 511